Clinical Trials in Special Populations: Challenges in Pregnant Women

Conducting clinical trials in special populations, particularly pregnant women, presents unique ethical, scientific, and regulatory challenges. Pregnancy induces significant physiological changes that can affect drug pharmacokinetics, pharmacodynamics, and the overall therapeutic response. This review addresses the barriers to enrolling pregnant women in clinical trials, including concerns about fetal safety, the lack of established dosing guidelines, and the limited representation of pregnant women in clinical research. We discuss the importance of evaluating drug safety and efficacy in pregnant populations, especially given that many medications are prescribed during pregnancy without comprehensive evidence of their effects. The review also highlights regulatory frameworks, such as the U.S. Food and Drug Administration’s (FDA) guidelines and the European Medicines Agency (EMA) recommendations, aimed at improving drug safety during pregnancy. We explore alternative study designs, including observational studies, the use of registries, and pharmacokinetic modeling, as ways to gather data while minimizing risks to both mother and fetus. Furthermore, we discuss the potential of pharmacogenomics and personalized medicine to tailor drug therapy during pregnancy. The review concludes by emphasizing the need for increased efforts to include pregnant women in clinical research, ensuring safer and more effective treatments for both mother and child.